What Is the MGFA Classification for Myasthenia Gravis?

The MGFA classification is a five-tier system developed by the Myasthenia Gravis Foundation of America that groups patients according to how severely the disease affects their muscles and which muscle groups are involved. It ranges from Class I, where only the eye muscles are affected, through Class V, which describes a life-threatening crisis requiring mechanical ventilation. The system also includes subclasses and a separate framework for tracking how patients respond to treatment over time, making it more layered than a simple severity ladder.

The Five Classes at a Glance

The MGFA classification sorts patients into five main classes based on which muscles are weak and how much that weakness limits function. Each class represents a step up in severity and involvement.

Class I is ocular myasthenia gravis. It includes patients whose weakness is confined to the muscles controlling the eyelids and eye movements, causing drooping eyelids (ptosis), double vision (diplopia), or both, with no weakness in the limbs, throat, or breathing muscles at any point during follow-up.¹ Many patients stay in this class permanently, but a meaningful fraction eventually develop generalized symptoms and shift to a higher class.

Class II is mild generalized myasthenia gravis. Weakness has spread beyond the eyes to affect limb muscles, throat and speech muscles, or both, but the weakness is still relatively mild and does not significantly interfere with daily tasks.²

Class III is moderate generalized MG. The same muscle groups are involved as in Class II, but weakness is more pronounced and begins to create noticeable limitations in everyday activities.

Class IV describes severe generalized disease, with marked weakness affecting muscles other than the eyes.³ Patients in this class often struggle with basic functions like chewing, swallowing, or holding their arms up.

Class V is myasthenic crisis. It applies to patients who need intubation or mechanical ventilation to breathe, with or without the use of a feeding tube. This is a medical emergency and the most dangerous state the disease can produce.⁴

What the A and B Subclasses Mean

For Classes II through IV, the MGFA system adds a letter to indicate which muscle groups are predominantly affected. Subclass A means weakness is mainly in the limbs or trunk muscles. Subclass B means weakness is mainly in the bulbar muscles, which control swallowing, chewing, and speech. Patients in subclass B can also have limb or trunk weakness, and vice versa; the letter reflects which group is more prominently affected, not the only group involved.

In practice, this distinction can be surprisingly tricky to pin down. A real-world study of patients in the United States and five European countries noted that the A and B subclasses are difficult to distinguish because patients often have overlapping involvement in both muscle groups, and clinicians in that study merged the subclasses for analysis.² The subclass still matters clinically because bulbar-predominant disease (B) tends to carry greater risk for swallowing and breathing difficulties, even within the same overall severity tier. But if your doctor records you as “Class IIA” or “Class IIB,” it reflects a judgment call about the dominant pattern rather than a clean anatomical boundary.

Post-Intervention Status

The MGFA framework does not stop at classifying severity at a single point in time. It also includes the Post-Intervention Status, or PIS, which tracks how a patient is doing after treatment. Where the five-class system describes where you are, the PIS describes where you have gotten to with therapy. The two systems work together to give a complete picture.

The PIS categories range from complete stable remission down to “worse.” Complete stable remission means a patient has had no signs or symptoms for at least a year and is taking no medication at all for the disease. Pharmacologic remission means no symptoms for at least a year, but the patient is still on some form of immunosuppressive therapy.⁵ Below remission sits minimal manifestations status, which means the patient still has some mild signs or symptoms. This category is further split into four subcategories (MM-0 through MM-3) based on whether the patient is on no treatment, immunosuppression alone, low-dose symptomatic medication, or a combination of both.⁵ Then there are “improved,” “unchanged,” and “worse,” which are straightforward clinical judgments.

One thing worth knowing is that the PIS is explicitly a clinical judgment call. It represents the evaluator’s overall impression of how the patient is doing, without requiring a defined change in any specific score on a standardized test.⁶ That makes it useful in clinical trials and routine care alike, because the physician synthesizes everything they observe rather than relying on a single number. Clinical trials of newer treatments like complement inhibitors have used the PIS to track whether patients reached minimal manifestations or pharmacologic remission at defined time points throughout the study.⁷

How MGFA Class Affects Daily Life

The classification is not just an abstract medical label. It maps onto meaningful differences in how much the disease disrupts a patient’s day-to-day activities. A study of patients across the United States and Europe assessed daily living impairment by MGFA class and found a clear, stepwise pattern. Patients in Class I had very low impairment scores, those in Class II had roughly double the impairment, and patients in Class III/IV had roughly triple the impairment of Class I patients. The differences were statistically significant even after adjusting for sex and other health conditions.²

What this means practically is that a Class I patient might deal with annoying double vision or a drooping eyelid but go about most of life normally. A Class II patient starts having trouble with tasks like brushing hair, carrying groceries, or speaking clearly. By Class III and IV, these difficulties become pronounced enough that patients may need help with routine activities, and every item measured across symptoms showed significant differences in severity by class.² This graded relationship has also been confirmed through psychometric validation: scores on the MG Activities of Daily Living scale reliably track with MGFA class, meaning the classification captures something real about functional burden.⁸

Does MGFA Class Predict How Patients Do Long-Term?

You might assume that starting at a higher MGFA class means worse outcomes permanently, but the relationship between baseline class and long-term prognosis is not perfectly linear. A prospective study found that all patients who presented at MGFA Class V (the most severe category, myasthenic crisis) eventually achieved minimal manifestations status. By comparison, about 91% of patients who started at Class II reached that same outcome.⁹ The difference was not statistically significant, which is a reminder that the MGFA class at diagnosis captures a snapshot in time, not a destiny. Patients who present in crisis often receive aggressive, rapid treatment, and that intensity of intervention can produce robust improvement.

That said, higher MGFA class at presentation does correlate with greater disease burden along the way. The classification’s prognostic value lies more in guiding treatment decisions than in predicting who will or will not recover. In a Chinese cohort of childhood-onset MG, higher MGFA class at presentation was an independent predictor of resistance to corticosteroid treatment, alongside factors like thymic abnormalities and disease duration before starting steroids.¹⁰ So while a higher class does not lock someone into poor outcomes, it does signal that the road to improvement may be harder.

Antibody Subtypes and Severity Patterns

The MGFA class a patient ends up in is partly shaped by which type of antibody drives their disease. Most MG patients carry antibodies against the acetylcholine receptor, the most common form. But a subset carries antibodies against a different protein called MuSK (muscle-specific kinase), and this group tends to land in higher MGFA classes.

A South African study found that individuals with MuSK antibodies had four times the odds of reaching MGFA Class IVB or V compared to patients who tested negative for all known antibodies.¹¹ A Taiwanese study echoed this pattern, finding that MuSK-MG patients were more likely to reach MGFA Class III or higher as their disease progressed, compared to other MG subtypes.¹² MuSK-MG disproportionately affects bulbar muscles, which explains why these patients are often classified in the “B” subclasses and face more swallowing and breathing difficulties.

Interestingly, the South African study also found that MuSK-MG patients were nine times more likely to eventually reach at least minimal manifestations status after a year or more of therapy, even though they started sicker.¹¹ This mirrors the earlier point about Class V patients doing surprisingly well long-term: aggressive disease does not always mean permanently severe disease, especially with targeted treatment. From a classification standpoint, knowing the antibody subtype adds important context to what the MGFA class number means for a given patient.

How the Classification Is Applied in Practice

The MGFA classification is meant to reflect a patient’s status at the time of examination, not a fixed label assigned once and never revisited. A task force recommendation specifies that the classification should be updated every three to six months to reflect current clinical status.⁶ A patient who starts at Class III and improves with treatment would shift to a lower class at subsequent visits. This makes the classification dynamic rather than historical, which is one of its strengths for ongoing care.

That said, the system has some inherent limitations in routine clinical use. Because the distinction between mild, moderate, and severe generalized disease (Classes II, III, and IV) depends on clinical judgment about the degree of weakness, different physicians may not always place the same patient in the same class. The A and B subclasses compound this ambiguity, as noted earlier. Research studies frequently merge adjacent classes for analysis precisely because the boundaries between them are soft. In the real-world study of U.S. and European patients mentioned above, Class III and IV patients were combined into a single group because there were too few in each separate class to analyze independently, and because the A/B distinction was too difficult for clinicians to apply consistently.²

None of this undermines the classification’s usefulness. The five-class system provides a common vocabulary that clinicians worldwide can share, and it works well for the purpose it was designed for: giving a broad picture of where a patient falls on the severity spectrum and how that position changes with treatment. The finer-grained work of quantifying symptom burden typically falls to scored outcome measures like the MG-ADL or quantitative MG score, which complement the MGFA class with actual numbers.

Childhood-Onset MG and the Same Classification

The MGFA system was developed with adult patients in mind, but it is also applied to children with MG. Childhood-onset MG has some distinct features that affect how the classification plays out. In large pediatric cohorts, ocular MG (Class I) is much more common at presentation than in adults, particularly among prepubertal children. A study of over 850 children in China found that pubertal-onset patients had a worse disease course than prepubertal patients, including a higher likelihood of generalized disease at presentation and higher MGFA classes overall.¹⁰

For parents navigating a child’s diagnosis, the MGFA class provides the same kind of shorthand it does for adults. A Class I diagnosis is reassuring in that it indicates disease limited to the eyes, though monitoring for generalization is still important. The caveat is that the transition from purely ocular to generalized disease is more fluid in children, with the risk of generalization varying by age of onset, antibody profile, and treatment timing. The classification captures the current state accurately, but in pediatric MG the state is especially prone to changing.

Older and Alternative Classification Systems

Before the MGFA system was published in 2000, the most widely used framework was the Osserman classification, developed decades earlier. The Osserman system also stratified patients by severity and pattern of muscle involvement, and it remains in use in some parts of the world. Both systems overlap considerably. Higher severity in either the MGFA or Osserman classification has been associated with more severe swallowing difficulties, for example.¹³

A recent study comparing classification systems for predicting MG relapse after thymoma surgery found an interesting wrinkle. While both the MGFA numerical classes and the Osserman system could distinguish patients at different risk levels for relapse, the risk did not always climb neatly with higher severity tiers in the MGFA numerical system. One group found that the three-year relapse risk was actually higher in MGFA group 2 than in MGFA group 3, suggesting the severity tiers do not always line up monotonically with risk.¹⁴ An antibody-based modification of the MGFA system actually outperformed the standard numerical classes in that study, hinting that combining clinical severity with serological data may produce sharper predictions than either one alone.

For patients and families, the practical takeaway is that the MGFA classification is the dominant system you will encounter in modern neurology clinics and clinical trial reports, but it was not designed to do everything. It works best as a snapshot of current clinical severity and a common language for communicating between doctors. It was never intended to replace scored assessments, antibody testing, or longitudinal tracking, and the system’s architects have always positioned it as one piece of a larger toolkit for understanding where a patient stands and where they are headed.

1
PLoS One. Comparative study of ocular and generalized myasthenia gravis in a South Korean cohort
2
PubMed Central. Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness
3
Scientific Reports. Factors associated with increased severity of generalized myasthenia gravis among patients in the United States and Europe
4
Arquivos de Neuro-Psiquiatria. The myasthenic patient in crisis: an update of the management in Neurointensive Care Unit
5
PubMed Central. Outcome measures and treatment effectiveness in late onset myasthenia gravis
6
PubMed. Standardization of Myasthenia Gravis Outcome Measures in Clinical Practice: A Report of the MGFA Task Force
7
PubMed. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension
8
PubMed Central. Psychometric properties of MG-ADL items and MG-ADL score
9
PubMed Central. Outcome Predictors of Generalized Myasthenia Gravis: A Prospective Observational Study
10
Pediatric Neurology. Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort
11
PubMed. Characteristics of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort
12
Acta Neurologica Taiwanica. Clinical Features and Outcome in Myasthenia Gravis Patients with Antimuscle-specific Tyrosine Kinase Antibody
13
PubMed. Swallowing Impairments in Patients with Myasthenia Gravis: A Scoping Review
14
JTCVS Open. Comparison of the performance of clinical classification systems for myasthenia gravis relapse after thymoma resection